Sars-CoV-2 infection in patients with cystic fibrosis. An overview
- PMID: 32921729
- PMCID: PMC7716958
- DOI: 10.23750/abm.v91i3.10391
Sars-CoV-2 infection in patients with cystic fibrosis. An overview
Abstract
The novel coronavirus SARS-CoV-2 was first identified in China in December 2019 and has since spread worldwide. People with Cystic Fibrosis (CF) have reduced survival mainly because of respiratory failure due to chronic pulmonary infections. Therefore, CF patients should be considered to have an increased risk of developing severe manifestations in case of SARS-CoV-2 infection. Surprisingly, the results of recent studies concerning SARS-CoV-2 infection in patients with CF show that in these patients the infection rate was lower than that of the general population. Various factors have been considered to explain a possible protective effect of CF against SARS-CoV-2 infection.
Conflict of interest statement
Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article
References
-
- World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 -11 March 2020. WHO. https://www.who.int/dg/speeches/detail/who-director-general-s-openingrem... .
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
